Comparison of Two Toric Contact Lenses on Current Toric Wearers
Launched by JOHNSON & JOHNSON VISION CARE, INC. · Mar 19, 2008
Trial Information
Current as of October 01, 2025
Completed
Keywords
ClinConnect Summary
Up to 7 sites in the US will participate. Each investigator will have both test and control lens types. There will be a maximum of 6 scheduled visits:
Visit 1: Habitual lens evaluation / Baseline / Trial fitting Visit 2: Dispensing (to be combined with Visit 1 where possible), Visit 3: Questionnaire only (no exam) 7 days (±2) after dispensing, Visit 4: 2 week follow-up 14 days (±3) after dispensing, and dispense second lens type, Visit 5: Questionnaire only (no exam) 7 days (±2) after 2nd lens dispense, Visit 6: 2 week follow-up 14 days (±3) after 2nd lens dispense
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Be at least 18 and less than or equal to 45 years of age, have a need for vision correction and wear contact lenses in BOTH eyes (monovision or uni-ocular fitting is NOT allowed).
- • 2. Be able to read J1 at near WITHOUT the aid of a near addition over the distance prescription.
- • 3. Be a currently successful wearer for at least 3 months of B\&L SofLens 66 Toric hydrogel lenses.
- • 4. Be able and willing to adhere to the instructions set forth in the protocol.
- • 5. Agree to wear their contact lenses in both eyes on a daily wear schedule for at least 8 hours per day every day during the study.
- • 6. Have a distance spectacle spherical component between -1.00 D and -5.25 D with cylinder in the range of 0.75 D to 2.25 D and cylinder axis within 10 ° of the vertical and within 30° of the horizontal in both eyes (when the subject's prescription is presented in minus cylinder form).
- • 7. Have a best corrected manifest refraction visual acuity of at least 20/25 or better in each eye.
- • 8. Be in good general health, based on his/her knowledge.
- • 9. Must be given an explanation of the study objectives, lens and solutions usage requirements and visit schedule. The subject must read, indicate understanding of and agree to begin participation in the clinical study. The subject must then sign the Informed Consent Form in the presence of the Investigator or their designee.
- Exclusion Criteria:
- • 1. Presbyopic or has the need for a near add for reading.
- • 2. Previous refractive surgery; current or previous orthokeratology treatment.
- • 3. Aphakia, keratoconus or a highly irregular cornea.
- • 4. The presence of ocular or systemic disease or has the need for medication (ocular or systemic) which might interfere with contact lens wear or which would cause the lenses to be removed more than twice a day. (e.g., Sjögren's syndrome, type II diabetes, allergies).
- • 5. A known history of corneal hypoesthesia (reduced corneal sensitivity.)
- • 6. Anterior uveitis or iritis (past or present).
- • 7. A history of recurrent erosions, corneal infiltrates corneal ulcer or fungal infections.
- • 8. Clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations or infections of the eye, eyelids, or associated structures.
- 9. Slit lamp findings that would contraindicate contact lens wear such as:
- • Pathological dry eye or associated findings
- • Pterygium or corneal scars within the visual axis
- • Neovascularization \>1mm in from the limbus
- • History of giant papillary conjunctivitis (GPC) worse than Grade 2
- • Meibomian gland dysfunction, blepharitis, or seborrhoeic dermatitis
- • 10. Current pregnancy or lactation (to the best of the subject's knowledge).
- • 11. Actively participating in another clinical study at any time during this study.
About Johnson & Johnson Vision Care, Inc.
Johnson & Johnson Vision Care, Inc. is a leading global company dedicated to advancing the field of eye health through innovative solutions and research. A subsidiary of Johnson & Johnson, it specializes in the development and manufacturing of contact lenses, surgical products, and vision correction technologies. With a commitment to improving the quality of life for individuals facing vision challenges, the company invests significantly in clinical trials and scientific research to ensure safety, efficacy, and optimal performance of its products. Johnson & Johnson Vision Care, Inc. is renowned for its robust portfolio that combines cutting-edge technology with a patient-centered approach, striving to enhance visual care for people around the world.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Morrow, Georgia, United States
Orlando, Florida, United States
Beachwood, Ohio, United States
Brentwood, Tennessee, United States
Jacksonville, Florida, United States
St Louis, Missouri, United States
Concord, North Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials